株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

未熟児網膜症 : パイプライン製品の分析

Retinopathy Of Prematurity - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 255964
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.77円で換算しております。
Back to Top
未熟児網膜症 : パイプライン製品の分析 Retinopathy Of Prematurity - Pipeline Review, H2 2017
出版日: 2017年09月30日 ページ情報: 英文 41 Pages
概要

未熟児網膜症(ROP)とは、未熟児の網膜脈管の発達を妨げる疾患です。通常は両眼のどちらにも現れ、幼児期の失明や長期的な視力低下の最も一般的な要因となっています。未熟児網膜症発症のリスク要因として、早産や超低出生体重、多胎出産などが挙げられます。

当レポートでは、世界各国での未熟児網膜症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

未熟児網膜症の概要

治療薬の開発

  • 未熟児網膜症向けパイプライン製品:概要
  • 未熟児網膜症治療薬:企業別
  • 未熟児網膜症治療薬:開発中の製品の一覧(企業別)

未熟児網膜症:治療薬の評価

  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

未熟児網膜症治療薬の開発に従事している企業

  • Biomar Microbial Technologies
  • F. Hoffmann-La Roche Ltd.
  • Recordati SpA

薬剤のプロファイル

休止中のプロジェクト

未熟児網膜症関連の製品開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9756IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2017, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 2 respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinopathy Of Prematurity - Overview
    • Retinopathy Of Prematurity - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Retinopathy Of Prematurity - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
    • Biomar Microbial Technologies
    • D. Western Therapeutics Institute Inc
    • F. Hoffmann-La Roche Ltd
    • Insmed Inc
    • Recordati SpA
  • Retinopathy Of Prematurity - Drug Profiles
    • Drug for Retinopathy of Prematurity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-09A0133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mecasermin rinfabate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propranolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Oncology, Diabetic Retinopathy and Retinopathy Of Prematurity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Retinopathy of Prematurity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinopathy Of Prematurity - Dormant Projects
  • Retinopathy Of Prematurity - Product Development Milestones
    • Featured News & Press Releases
      • Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
      • Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Retinopathy Of Prematurity, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H2 2017
  • Retinopathy Of Prematurity - Pipeline by D. Western Therapeutics Institute Inc, H2 2017
  • Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Retinopathy Of Prematurity - Pipeline by Insmed Inc, H2 2017
  • Retinopathy Of Prematurity - Pipeline by Recordati SpA, H2 2017
  • Retinopathy Of Prematurity - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Retinopathy Of Prematurity, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top